The Santa Rosa Institute today announced that testing of the drug Genuflex on 1,613 mice did not reach statistical significance in the pre-defined primary endpoint: increased life span with no side effects at six months of treatment. This will delay the filing of a Biologics License Application (BLA) with the U.S. Food and Drug Administration.

Isaac Muzischenko, Head of Clinical Development at the Institute, commented: "Though side effects generated by long-term Genuflex treatment were statistically significant, the trial did generate provocative data about dosage and safety in mice. This is an important finding for one of Genuflex' approved indications, cancer treatment. We are encouraged by these findings over the long term and will continue to evaluate the use of Genuflex in other indications. The Santa Rosa Institute is in the process of preparing new trial programs for Genuflex."

The full findings of the trial, including subgroup analyses, will be presented at the American Longevity Society meeting, December 17-21, in Atlanta.

About the Santa Rosa Institute

The Santa Rosa Institute, winner of the U.S. National Medal of Technology, is a leading biotechnology company that discovers and develops human pharmaceuticals for significant unmet medical needs. The company has its headquarters in Albuquerque, New Mexico.